TY - JOUR

T1 - Animal inflammation-based models of depression and their application to drug discovery

AU - Ma, Li

AU - Demin, Konstantin A.

AU - Kolesnikova, Tatyana O.

AU - Kharsko, Sergey L.

AU - Zhu, Xiaokang

AU - Yuan, Xiaodong

AU - Song, Cai

AU - Meshalkina, Darya A.

AU - Leonard, Brian E.

AU - Tian, Li

AU - Kalueff, Allan V.

N1 - Funding Information: L Tian is supported by the European Commission FP7/Cooperation subprogram HEALTH-2013-Innovation Grant 602919 and Magnus Ehrnrooth Foundation. C Song is supported by the National Natural Science Fund of China grants 81171118 and 81471223. AV Kalueff is supported by the Russian Foundation for Basic Research grant 16-04-00851. His research laboratories are supported by Guangdong Ocean University, St. Funding Information: Petersburg State University and Ural Federal University (Government of Russian Federation Act 211, contract 02-A03.21.0006). X Zhu is funded by the Fundamental Research Funds for the Central Universities of China (XDJK2016C071). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2017 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Depression, anxiety and other affective disorders are globally widespread and severely debilitating human brain diseases. Despite their high prevalence and mental health impact, affective pathogenesis is poorly understood, and often remains recurrent and resistant to treatment. The lack of efficient antidepressants and presently limited conceptual innovation necessitate novel approaches and new drug targets in the field of antidepressant therapy. Areas covered: Herein, the authors discuss the emerging role of neuro-immune interactions in affective pathogenesis, which can become useful targets for CNS drug discovery, including modulating neuroinflammatory pathways to alleviate affective pathogenesis. Expert opinion: Mounting evidence implicates microglia, polyunsaturated fatty acids (PUFAs), glucocorticoids and gut microbiota in both inflammation and depression. It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways. In addition, the authors call for a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved (and therefore, core) neuro-immune mechanisms of depression.

AB - Introduction: Depression, anxiety and other affective disorders are globally widespread and severely debilitating human brain diseases. Despite their high prevalence and mental health impact, affective pathogenesis is poorly understood, and often remains recurrent and resistant to treatment. The lack of efficient antidepressants and presently limited conceptual innovation necessitate novel approaches and new drug targets in the field of antidepressant therapy. Areas covered: Herein, the authors discuss the emerging role of neuro-immune interactions in affective pathogenesis, which can become useful targets for CNS drug discovery, including modulating neuroinflammatory pathways to alleviate affective pathogenesis. Expert opinion: Mounting evidence implicates microglia, polyunsaturated fatty acids (PUFAs), glucocorticoids and gut microbiota in both inflammation and depression. It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways. In addition, the authors call for a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved (and therefore, core) neuro-immune mechanisms of depression.

KW - депрессия

KW - аффективная социальная информация

KW - животные модели

KW - нейровоспаление

UR - http://www.scopus.com/inward/record.url?scp=85028764787&partnerID=8YFLogxK

U2 - 10.1080/17460441.2017.1362385

DO - 10.1080/17460441.2017.1362385

M3 - Review article

C2 - 28816544

AN - SCOPUS:85028764787

VL - 12

SP - 995

EP - 1009

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 10

ER -